Dergiler / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 1

Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer

Sayfa
56–60
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Tissue Doppler imaging may be more sensitive than ECG, conventional ECHO and Doppler for determining the subclinical cardiac damage.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Cardiac effects of chemotherapy are usually recognized after clinical symptom or sign occurrence in patients with breast cancer.
📊
Temel Bulgular & Veri:After 6 months, detailed ECG and ECHO examinations were repeated and compared with baseline values.
💡
Sonuç & Katkı:Tissue Doppler imaging may be more sensitive than ECG, conventional ECHO and Doppler for determining the subclinical cardiac damage.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Cardiac effects of chemotherapy are usually recognized after clinical symptom or sign occurrence in patients with breast cancer. In this study, we aimed to determine the potential subclinical cardiotoxic effects of chemotherapy that were given lower dosage than well known cardiac safety dosage limits in patients with breast cancer during early period.Methods: Fifty-one patients consecutively enrolled to this prospective cohort study. All patients were diagnosed as breast cancer at oncology hospital in University of Gaziantep. Before chemotherapy, all of the patients underwent to detailed ECG and echocardiography (ECHO) examinations. After 6 months, detailed ECG and ECHO examinations were repeated and compared with baseline values. Statistical analysis was performed using Shapiro-Wilk tests, Student t-test and Spearman correlation test.Results: The average age of patients was 51 and one was male. Statistically significant decrease in ejection fraction was found after treatment (62.3%±3.3 and 59.9%±5.9, p=0.002). Evaluation of diastolic parameters; significant increase in the transmitral A flow velocity and significant decrease of E/A ratio were observed on Doppler ECHO analysis (77.4±19.1 cm/sec versus 86±18 cm/sec, p<0.001; 1.01±0.3 versus 0.9±0.2, p=0.03, respectively). On tissue Doppler analysis we observed that significant reduction in the value of E' and significantly increase E/E' ratio were present (12.5±3.6 cm/sec versus 10.7±2.9 cm/sec, p=0.001; 6.6±2.9 versus 7.7±3.3, p=0.04, respectively).Conclusion: Chemotherapy has detrimental subclinical effect on both of systolic and diastolic function in early six months period despite the prescription of lower dosage of chemotherapy than well-known cardiac safety dosage limits. Tissue Doppler imaging may be more sensitive than ECG, conventional ECHO and Doppler for determining the subclinical cardiac damage.

🔖

Bu Makaleye Atıf Yap

ALICI, H., BALAKAN, O., ERCAN, S., ÇAKICI, M., YAVUZ, F., DAVUTOĞLU, V. (2015). Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 1, 56–60. https://ajindex.com/articles/365894

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Hong RA, Iimura T, Sumida KN, Eager RM. Cardio-oncology/onco- cardiology. Clin Cardiol 2010; 33: 733-7. [CrossRef] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. [CrossRef] DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin 2011; 61: 409-18. [CrossRef] Hossain A, Chen A, Ivy P, Lenihan DJ, Klatman J, Taddei-Peters W, et al. The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting. Heart Fail Clin 2011; 7: 373-84. [CrossRef] Gillespie HS, McGann CJ, Wilson BD. Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardiol Rev 2011; 7: 234-44. [CrossRef] Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-70. [CrossRef] Mann DL, Krone RJ. Cardiac disease in cancer patients: an overview. Prog Cardiovasc Dis 2010; 53: 80-7. [CrossRef] Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58. [CrossRef] Allen A. The cardiotoxicity of chemotherapetic drugs. Semin Oncol 1992; 19: 529-42.
  2. Tolba KA, Deliargyris EN. Cardiotoxicity of cancer therapy. Cancer Invest 1999; 17; 408-22. [CrossRef] Wu AH. Cardiotoxic drugs: clinical monitoring and decision making. Heart 2008; 94: 1503-9. [CrossRef] Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-9. [CrossRef] Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracyclines treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7: 141-6. [CrossRef] Fumoleau P, Roché H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, et al; French adjuvant study group. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006; 17: 85-92. [CrossRef] Baldini E, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, et al. Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.